These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25115206)

  • 1. [Hyperglycaemia during treatment with everolimus].
    Opdam FL; Huitema AD; Beijnen JH; Schellens JH
    Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E; Zelnak A; O'Regan R
    Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
    Martinet W; De Loof H; De Meyer GRY
    Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are we missing the mTOR target in breast cancer?
    Johnston SR
    Breast Cancer Res Treat; 2011 Aug; 128(3):607-11. PubMed ID: 20953834
    [No Abstract]   [Full Text] [Related]  

  • 6. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
    Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
    Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
    Tobinai K; Ogura M; Maruyama D; Uchida T; Uike N; Choi I; Ishizawa K; Itoh K; Ando K; Taniwaki M; Shimada N; Kobayashi K
    Int J Hematol; 2010 Nov; 92(4):563-70. PubMed ID: 20972652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J
    Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.
    Yardley DA
    Clin Breast Cancer; 2014 Oct; 14(5):297-308. PubMed ID: 25065566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
    Peddi PF; Shatsky RA; Hurvitz SA
    Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in the treatment of hormone receptor-positive breast cancer.
    Chavez-MacGregor M; Gonzalez-Angulo AM
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of everolimus in renal cell cancer.
    Amato R; Stepankiw M
    Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
    Hadji P; Coleman R; Gnant M
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
    Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
    N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
    Peterson ME
    Support Care Cancer; 2013 Aug; 21(8):2341-9. PubMed ID: 23686401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.